Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
The Journal of Biological Chemistry|August 24, 2005
Identification of residues responsible for ligand recognition and regioisomeric selectivity of lysophosphatidic acid receptors expressed in mammalian cellsYuko Fujiwara, Vineet Sardar, Akira Tokumura, et al.
Annals of the New York Academy of Sciences|January 16, 2010
Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseasesMichael Elliott, Jacqueline Benson, Marion Blank, et al.
Annals of the Rheumatic Diseases|May 26, 2010
Both structural damage and inflammation of the spine contribute to impairment of spinal mobility in patients with ankylosing spondylitisPedro Machado, Robert Landewé, Jürgen Braun, et al.
Arthritis and Rheumatism|February 5, 2010
Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled studyJoel Kremer, Christopher Ritchlin, Alan Mendelsohn, et al.
Spine|May 28, 2003
The natural history of spondylolysis and spondylolisthesis: 45-year follow-up evaluationWilliam J Beutler, Bruce E Fredrickson, Albert Murtland, et al.
The Journal of Biological Chemistry|April 4, 2002
Multiple mechanisms linked to platelet activation result in lysophosphatidic acid and sphingosine 1-phosphate generation in bloodTakamitsu Sano, Daniel Baker, Tamas Virag, et al.
Arthritis and Rheumatism|September 2, 2006
IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritisSudha Visvanathan, Carrie Wagner, Josef Smolen, et al.
The Journal of Rheumatology|November 18, 2011
Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumabPeter C Taylor, Christopher Ritchlin, Alan Mendelsohn, et al.
Annals of the Rheumatic Diseases|November 12, 2010
Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scoresPedro Machado, Robert Landewé, Elisabeth Lie, et al.
Annals of the Rheumatic Diseases|June 5, 2012
Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trialMichael E Weinblatt, Clifton O Bingham, Alan M Mendelsohn, et al.
Pageof 8